Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78 945 patients

Diabetes, Obesity and Metabolism

Volumn 14, Issue 3, 2012, Pages 228-233

  Esposito, K ^a   Chiodini, P ^a   Bellastella, G ^a   Maiorino, M I ^a   Giugliano, D ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antidiabetic drug; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; SULFONYLUREA;

ARTICLE; CLINICAL PRACTICE; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW;

EID: 84857029848     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01512.x     Document Type: Article

References (16)

1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008; 168: 2088-2094.
2. Hirsch IB. Insulin analogues. New Engl J Med 2005; 352: 174-183.
3. Executive summary: standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl 1): S4-10.
4. Nathan DM, Buse J, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
6. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl 1): S1-201.
7. Centre for Clinical Practice at NICE. Type 2 diabetes: newer agents. NICE short clinical guideline 87, 2009.
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 360 reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W-65-94.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
10. Stuart A, Ord JK. Kendall's Advanced Theory of Statistics, 6th edn. London: Edward Arnold, 1994.
11. Deeks JJAD, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger MD-SG Altman DG eds. Systematic Reviews in Health Care. London: BMJ Publishing, 2001; 285-312.
12. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624.
13. Centers for Disease Control and Prevention. Diabetes data and trends. 2009. Available from URL: Accessed 19 April 2011.
14. National Center for Health Statistics. Health, United States, 2009: with special feature on medical technology. Hyattsville, MD; 2010: 95.
15. National Committee for Quality Assurance. The State of Health Care Quality 2010, Report [article online]. Washington, DC: National Committee for Quality Assurance. Available from URL: Accessed October 2011.
16. Rossi MC, Nicolucci A, Arcangeli A, et al. Baseline quality of care data from a quality improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care 2008; 31: 2166-2168.